GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Experts express alarm that GLP-1 RAs may trigger or worsen eating disorders. But is there any role they might play in binge ...

So-called GLP-1 supplements, named to echo the class of glucagon-like peptide-1 agonist drugs that includes Wegovy and Zepbound, are likely to be ineffective for weight loss. “If you can buy it ...

Lexaria Bioscience (LEXX) provides a glucagon-like peptide-1 strategic update following important industry developments reported both by Pfizer ...

Patients using GLP-1 receptor agonists appear to have a lower risk of age-related macular degeneration and primary open-angle glaucoma. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs ...

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

Use of GLP-1 receptor agonists was associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor ...